Research and Markets: DRG Insight: Rheumatoid Arthritis (G7) The Herald | HeraldOnline.com Biologics from other drug classes - the interleukin-6 inhibitor tocilizumab (Roche/Chugai's Actemra/RoActemra), the selective costimulation modulator abatacept (Bristol-Myers Squibb/Ono Pharmaceutical's Orencia), and the B-cell-targeted therapy ... |
